Abaxis (Abaxis) Change In Receivables : $-7.5 Mil (TTM As of Mar. 2018)

View and export this data going back to 1992. Start your Free Trial

What is Abaxis Change In Receivables?

Abaxis's change in receivables for the quarter that ended in Mar. 2018 was $-7.8 Mil. It means Abaxis's Accounts Receivable increased by $7.8 Mil from Dec. 2017 to Mar. 2018 .

Abaxis's change in receivables for the fiscal year that ended in Mar. 2018 was $-7.5 Mil. It means Abaxis's Accounts Receivable increased by $7.5 Mil from Mar. 2017 to Mar. 2018 .

Abaxis's Accounts Receivable for the quarter that ended in Mar. 2018 was $48.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Abaxis's Days Sales Outstanding for the three months ended in Mar. 2018 was 64.71.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Abaxis's liquidation value for the three months ended in Mar. 2018 was $174.6 Mil.

Abaxis Change In Receivables Historical Data

The historical data trend for Abaxis's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abaxis Change In Receivables Chart

Abaxis Annual Data

Trend

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Change In Receivables

Get a 7-Day Free Trial

11.17

-1.31

-4.91

-4.56

-7.47

Abaxis Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18
Change In Receivables	Get a 7-Day Free Trial															-5.29	-3.33	3.29	0.36	-7.79

Abaxis Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.5 Mil.

Abaxis (NAS:ABAX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Abaxis's Days Sales Outstanding for the quarter that ended in Mar. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	48.164	/	67.918	*	91
=	64.71

2. In Ben Graham's calculation of liquidation value, Abaxis's accounts receivable are only considered to be worth 75% of book value:

Abaxis's liquidation value for the quarter that ended in Mar. 2018 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	166.783	-	50.41	+	0.75 * 48.164	+	0.5 * 44.121
=	174.6

Abaxis Change In Receivables Related Terms

Thank you for viewing the detailed overview of Abaxis's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Abaxis (Abaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abaxis Inc (NAS:ABAX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.abaxis.com

Abaxis Inc manufactures point-of-care blood analysis instruments and consumables for medical and veterinary care providers. The medical segment sells Piccolo Chemistry Analyzers, which can provide results about a blood sample in 12 minutes, and related reagents to physicians, hospitals, pharmacies, and other healthcare providers. The veterinary segment generates the majority of the firm's total revenue and sells products to animal hospitals, veterinary clinics, and private research laboratories. Products in this segment include the VetScan VS2 chemistry analyzer, animal-specific reagents, and rapid tests for canine and feline diseases. The vast majority of the firm's revenue comes from North America and Europe.

Executives

Richard Bastiani	director	C/O ABAXIS INC, 3240 WHIPPLE RD, UNION CITY CA 94587
Taylor Dean Ross Jr	officer: CFO and VP of Finance	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Clinton Severson	director, officer: CEO & Board Chairman	C/O ABAXIS INC, 3240 WHIPPLE ROAD, UNION CITY CA 94587
Michael D Casey	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020